Le Lézard
Classified in: Health
Subjects: NPT, PET, ANW

Morris Animal Foundation Funds New Study to Advance Osteosarcoma Treatment in Dogs


DENVER, Jan. 13, 2023 /PRNewswire/ -- A new therapeutic trial hopes to change the outcomes for dogs suffering from osteosarcoma, a deadly form of bone cancer. The study, funded by Morris Animal Foundation, will be conducted by a veterinary research team at the University of Minnesota.

Led by Dr. Jessica Lawrence, Associate Professor of Radiation Oncology, the study team's goal is to test a novel immunotherapy first in the laboratory, and then in a select group of dogs with osteosarcoma to assess efficacy. If successful, the treatment could be a powerful new tool to treat osteosarcoma in dogs.

"Immunotherapy, or treatment that boosts the body's immune response against cancer, is one of the most exciting recent advances in the treatment of tumors," said Dr. Lawrence. "There are few immunotherapy options specifically for dogs; for this reason, we are incredibly grateful for support from Morris Animal Foundation to develop a new immunotherapy approach for giant-breed dogs with osteosarcoma. Osteosarcoma is good at masking itself to the body's immune system, so it can grow and spread. We hope this work will result in a new way to boost the immune system and provide hope for pet owners and oncologists faced with this terrible cancer."

Osteosarcoma is the most common primary bone tumor diagnosed in dogs. The cancer disproportionately affects the long bones of large- and giant-breed dogs. Current treatment regimens include limb amputation, chemotherapy and radiation therapy, but some dogs are poor candidates for surgery. Effective immunotherapy would be a welcome therapeutic option for these patients.

"New treatments are desperately needed for canine osteosarcoma, and immunotherapy treatments often have the advantage of fewer side effects," said Dr. Kathy Tietje, Morris Animal Foundation Vice President, Scientific Operations. "This study could help improve outcomes and quality of life for dogs with osteosarcoma, particularly those that are poor surgical candidates."

Cancer impacts animals worldwide and is a leading cause of death in dogs over the age of 2. Since 1962, Morris Animal Foundation has funded more than 300 cancer studies, invested nearly $40 million, and continues to make strides against the disease.

About Morris Animal Foundation

Morris Animal Foundation's mission is to bridge science and resources to advance the health of animals. Founded in 1948 and headquartered in Denver, it is one of the largest nonprofit animal health research organizations in the world, funding more than $149 million in nearly 3,000 critical studies across a broad range of species. Learn more at morrisanimalfoundation.org.

SOURCE Morris Animal Foundation (MAF)


These press releases may also interest you

at 07:35
Brandwidth Solutions, a full-service, B2B science-focused marketing communications agency, today announced the launch of its custom marketing ROI platform, LeadInsitesTM, engineered to address the evolving complexities of data tracking and...

at 07:35
Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in Vienna,...

at 07:30
JanOne Inc. , a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024....

at 07:30
June is a time when Americans celebrate fathers. But fatherhood isn't joyful for the thousands of dads experiencing perinatal mental health disorders (PMHDs), and many of them suffer alone. Societal norms and expectations contribute to the prevalence...

at 07:23
Straine Dental Management (SDM), a dentist-owned, dentist-led dental services organization (DSO), is delighted to announce its expansion into Maine. This strategic affiliation of three renowned dental practices led by Shilo Annis, DMD ? Breakwater...

at 07:13
SciBase Holding AB ("SciBase") (STO: SCIB), SciBase, a leading developer of AI-based solutions for skin diseases, today announces that Leda Beaty has been appointed Head of US Commercial Operations. SciBase is pleased to announce that Leda will be...



News published on and distributed by: